Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 5/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | IDE | P14735 | 4/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14609867 | 0.86 | SMN1; SMN2 (0.40) | SMN1; SMN2TSHRLMNACYP1A2CYP3A4 | |
| SCHEMBL5213997 | 0.85 | MAPK1 (0.53) | KDM4ESMN1; SMN2LMNACYP3A4CYP2D6 | |
| SCHEMBL5209936 | 0.85 | LMNA (0.50) | PKMSMN1; SMN2TSHRLMNACYP1A2 | |
| SCHEMBL5209966 | 0.84 | SMN1; SMN2 (0.46) | NAMPTKDM4EPKMSMN1; SMN2LMNA | |
| SCHEMBL14609769 | 0.84 | SMN1; SMN2 (0.41) | SMN1; SMN2TSHRLMNA | |
| SCHEMBL5211614 | 0.83 | TSHR (0.40) | SMN1; SMN2TSHRLMNAPOLB | |
| SCHEMBL5213360 | 0.83 | CYP2D6 (0.45) | KDM4ESMN1; SMN2TSHRLMNACYP1A2 | |
| SCHEMBL5207799 | 0.83 | ENPP2 (0.45) | SMN1; SMN2TSHRLMNANPSR1 | |
| SCHEMBL14609887 | 0.83 | ATM (0.42) | SMN1; SMN2TSHRLMNA | |
| SCHEMBL5206933 | 0.82 | ENPP2 (0.47) | TDP1SMN1; SMN2LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7183276-B2 | Azole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-27 | — | — | US | disclosed |
| US-20050090534-A1 | Azole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-04-28 | — | — | US | disclosed |
| EP-1486490-A1 | AZOLE COMPOUNDS | Takeda Chemical Industries, Ltd. (JP) | 2004-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090534-A1 | Azole compounds | AHR, NR0B2, NR2C2 | NAMPT 1063/4885KDM4E 2428/4885TDP1 4271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.